innoscripta Shares Swing Wildly as Tax-Fraud Probe Puts Business Model Under Scrutiny
Published on 10/03/2026 at 01:10 | Editorial boerse-global.de
Investigators descended on innoscripta SE's offices in Tutzing and Munich on Thursday, and the fallout has been swift and brutal for shareholders. The search was carried out under two warrants issued by the Schwäbisch Gmünd district court on 3 August and 15 September 2026, tied to suspicions that the company aided clients in obtaining unjustified tax benefits through research allowance applications.
Friday's session laid bare the market's whiplash. The stock clawed back as much as 9.7% at one point to trade at EUR 41.30, yet earlier in the day it had plumbed a fresh 52-week low of EUR 33.05 before settling at EUR 36.50 — a further daily loss of 3.0%. That intraday range tells its own story: no one is quite sure whether this is a survivable blow or an existential one.
innoscripta was quick to push back. The company said the matters under investigation do not, on current knowledge, relate to business conducted in the 2026 financial year, and that day-to-day operations continue unimpeded. It also stressed that an employee connected to the case left the firm several years ago. Even so, the mere fact of a state raid strikes at the regulatory credibility on which the entire equity story has rested.
The certification process sits at the heart of the matter
What market participants are now trying to work out is whether this is the isolated misconduct of a former staffer or a sign of deeper structural cracks running through the advisory and billing model. The answer will determine the company's future earnings power.
innoscripta's business leans heavily on the Bescheinigungsstelle Forschungszulage (BSFZ), the German body that pre-assesses the technical eligibility of projects. In almost every case, the service provider's contractual fee claim crystallises the moment that BSFZ certificate is issued. Only afterwards does the client's tax office set the actual research allowance. Clients or their tax advisers review the data in the software themselves and file the assessment request. Should investigators establish that data was systematically manipulated, this multi-stage process would become the focal point of future liability questions.
Should investors sell immediately? Or is it worth buying innoscripta?
Warburg pulls its target as the valuation's assumptions unravel
Warburg Research wasted no time, suspending both its rating and its EUR 225 price target. The analysts made clear that the target had presupposed a fully intact business model and a sustainable EBIT margin of 55%. On top of that, roughly 56% of the company's value in the DCF model was derived from terminal value — precisely the long-term earnings expectation now under threat. Warburg flagged specific dangers: client attrition in new business, clawback demands, liability claims from affected clients and possible corporate penalties. It said it would only resume coverage once the facts are fully clarified.
That the market reaction was so violent says much about how fragile the prior valuation had become. Margins and growth forecasts of that magnitude can only be justified while the business model holds together. If market access erodes through reputational damage, or regulatory tightening forces a fundamental rethink, those calculations collapse.
A path back exists — but it depends on the probe staying narrow
For a genuine recovery scenario to take hold, the investigation would need to remain confined to a handful of legacy cases. Management under CEO Michael Hohenester points out that tax offices across Germany have already assessed several thousand research allowances for the firm's clients, with those grants confirmed in numerous audits. Internal processes and the software have also been reviewed externally on legal and tax grounds on multiple occasions, including ahead of the May 2025 IPO. If the company's account holds — that current business is untouched and cooperation with investigators defuses the allegations — operating growth could stay intact, and today's valuation would look like an overcorrection that fails to reflect a healthy core business.
The alternative is far grimmer. Should the aiding-and-abetting allegation be confirmed, affected clients face back-payments that could flow back to innoscripta through recourse claims. A drawn-out affair looms, one that would burn through legal costs while paralysing new business.
What investors should watch next
Direction over the coming weeks hinges on how the authorities classify the case. As long as proceedings stay limited to the former employee and no further allegations are levelled at current decision-makers, the shares have a basis for stabilising. If that assumption breaks — through an expansion of the probe to additional mandates or current financial years — lasting damage to the margin becomes the likely outcome.
The next concrete date on the calendar is an announced product presentation for shareholders at the Tutzing site, with exact timing to be communicated shortly. Management will have to field pressing questions there about the integrity of its software and its internal compliance standards. Only that clarity is likely to show whether investor trust can be rebuilt.
Ad
innoscripta Stock: New Analysis - 3 October
Fresh innoscripta information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
